Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07296354

Evaluation of an ATP-Containing Parenteral Vitamin B Complex in Patients With Symptomatic Diabetic Polyneuropathy

Epinosine B Forte ampoule is an intramuscular injectable supplement containing adenosine triphosphate (ATP), Cocarboxylase (vitamin B1 derivative), vitamin B12, and nicotinamide (vitamin B3). It is used to support nerve function, treat B vitamin deficiencies, enhance cellular energy metabolism, and alleviate symptoms of fatigue, neuropathy, and general weakness. Commonly prescribed for conditions like peripheral neuritis and recovery from nerve-related disorders. Side effects are generally mild and may include local injection site reactions or allergic responses. Clinical evaluation of this investigational product may provide valuable evidence for its efficacy in treating diabetic neuropathy where impaired energy metabolism and micronutrient deficits often coexist. Establishing the efficacy and safety of Epinosine B Forte through a structured clinical trial is therefore essential. Demonstrating clinical benefit would not only inform and optimize current treatment protocols for DPN but also support the potential for broader clinical application which includes routine use in diabetic care, integration into treatment guidelines, and possible extension to other neuropathic conditions where metabolic support may play a therapeutic role

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Neuropathic Pain Nervous System Diseases Neuralgia Neurologic Manifestations Neuromuscular Diseases Pain Pathological Conditions, Signs and Symptoms Peripheral Nervous System Diseases Signs and Symptoms

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

About this study

To evaluate the effectiveness of the IMP (Epinosine - B Forte Lyophilized Ampoules) compared to an active control (vitamin B complex only) in improving neuropathic symptoms in patients with symptomatic diabetic polyneuropathy based on a validated neurological symptom scoring system.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients ≥ 18 years of age at time of consent
  • Able to provide informed consent for study participation.
  • Diagnosed with either Type 1 or Type 2 diabetes mellitus, with glycated hemoglobin (HbA1c) ≤ 10%
  • Diagnosed with diabetic polyneuropathy, defined as a Diabetic Neuropathy Symptom (DNS) score ≥ 2, with symptom duration of at least 3 months prior to providing informed consent.
  • Willingness to comply with study procedures and attend scheduled study visits
  • Patients should be on a stable antidiabetic medication regimen for 30 days prior to randomization.

Exclusion criteria

-

  • Non-diabetic causes of neuropathy, e.g., alcohol abuse, vitamin B12 deficiency, renal failure, or chemotherapy-induced neuropathy other diseases that causes presence of any severe pain associated with conditions other than DPN that may confuse or confound the assessment of neuropathic pain.
  • Current or recent (within 30 days from screening visit) use of Neuropathic pain treatments, including:

2.1 Gabapentinoids (gabapentin, pregabalin),

2.2Serotonin-norepinephrine reuptake inhibitors (duloxetine, venlafaxine, desvenlafaxine)

2.3 Tricyclic antidepressants (e.g., amitriptyline) 2.4 Topical capsaicin preparations 2.5 Carbamazepine, 2.6 Oxcarbazepine, 2.7 Lamotrigine 2.8 topiramate 2.9 other agents for neuropathic pain , Sedatives and anxiolytics (Benzodiazepines, Z-drugs (e.g., zolpidem), Barbiturates, Other B-complex or ATP-containing injectable supplements 2.10 Multivitamins or nutritional supplements 2.11 Pentoxifylline or Naftidrofuryl oxalate, Alpha-lipoic acid or other drug classes indicated for treatment of neuropathic pain.

  • Severe comorbidities (e.g., malignancy, liver failure, end-stage renal disease, decompensated heart failure)
  • Pregnancy or breastfeeding
  • Female patients of childbearing potential not using effective contraception (e.g., oral contraceptives, DMPA, IUD, double barrier, sterilization, or confirmed postmenopausal status)
  • Known hypersensitivity to any component of the investigational product
  • Participation in another clinical trial within the past 3 months

Treatment and study plan

Adenosine triphosphate

Drug

Each lyophilized ampoule contains:

Adenosine Triphosphate (ATP) - 10 mg Cocarboxylase (Vitamin B1 derivative) - 50 mg Nicotinamide (Vitamin B3) - 20 mg Vitamin B12 (Cyanocobalamin) - 500 mcg

Vitamin B Complex

Drug

Each ampoule contains:

Cocarboxylase 50 mg Vitamin B12 500 mcg Nicotinamide 20 mg

Primary outcomes

  1. To compare the mean change in Diabetic Neuropathy symptoms Score (DNS) from baseline to week 12 between the two study arms

    Time frame: 12 weeks

    A simplified scoring system, the diabetic neuropathy symptom score (DNS) frequently used in clinical trials and medical practice , assessing pain, numbness, tingling and ataxia. The maximum score of DNS is four points, one point or more indicates neurological abnormalities . It was reported to be validated, fast and easy to perform, with a high predictive value when screening for diabetic polyneuropathy . DNS was found to be the most and modified NDS had equal specificity (100%). DNS had a better diagnostic efficacy (70 %) ]sensitive test (65.4%)

Secondary outcomes

  1. Neuropathy- and foot ulcer-specific quality of life (Neuro-QoL)

    Time frame: 12 weeks

    Neuro-QoL (Quality of Life in Neurological Disorders) is a validated patient-reported outcome measurement system developed to assess the physical, mental, and social health-related quality of life (HRQoL) in individuals living with neurological conditions. It is applicable across various disorders, including diabetic polyneuropathy.

    The version used in this study consists of 35 items, grouped into the following components:

    • 27 items covering six life domains: o Pain (7 items)
    • Loss or reduction of sensitivity (3 items)
    • Diffuse sensory-motor symptoms (3 items)
    • Limitations in daily activities (3 items)
    • Interpersonal problems (4 items)
    • Emotional distress (7 items)
    • 6 global items, one appended to each domain (labeled A-F), assessing the overall perceived impact of that domain on HRQoL.
    • 2 final items: o One assessing the overall impact of foot problems on HRQoL.
    • One providing a general global rating of the participant's HRQoL.

  2. Vibration perception threshold

    Time frame: 12weeks

    The VPT will be tested on the pulp of the large toe of either right or left foot. Average of three measurements will be taken to calculate the VPT value of the given patient. Values will be recorded in the CRF. The VPT values will be graded as 'normal' (<15v), 'mild' (15-20v), 'moderate' (20-25v) and >25 as 'severe' neuropathy ( Martin, C.L., et al.,, 2010).

Study contacts

Contact information is provided by the study sponsor or research team.

Mohamed A Momtaz, pHD

CONTACT

[email protected]

00201008676724

Sponsors and collaborators

Lead sponsor

Egyptian International Pharmaceutical Industries Co

Industry

Registry information

Official study title

Randomized, Double-Blind Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of an ATP-Containing Parenteral Vitamin B Complex in Patients With Symptomatic Diabetic Polyneuropathy

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Dec 22, 2025
Registry last updated
Dec 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.